https://www.accord-trial.org/

ACCORD 2 Newsletter

30th June 2020

ACCORD – a national Phase 2, CMO prioritised study funded by UKRI and supported by the NIHR to develop the next generation of drugs for COVID-19.

The drugs currently in trial are:

- **Bemcentinib** – AXL inhibitor which may prevent viral infection and lung inflammation
- **Acalabrutinib** – a Bruton's tyrosine kinase (BTK) inhibitor
- **MEDI3506** – an anti-IL-33 monoclonal antibody
- **Zilucoplan** – a complement C5 inhibitor that could block severe inflammatory responses

Active ACCORD Sites

At the moment here are discussions going on with over 15 sites to hopefully come on board with the ACCORD family.

Recruitment Figures so far:

Arm 002 Bemcentinib - 4
Arm 003 Acalabrutinib - 7
Arm 004 MEDI3506 - 6
Arm 006 Zilucoplan - 5

Our congratulations to Wythenshawe and Glenfield Hospitals on their first recruit.

Site contacts at IQVIA

IQVIA have a set of CRA's (or monitors) that will be your point of contact for the duration of the study, should these change you will be informed directly by the CRA and via this newsletter.

Arm 002 Bemcentinib - Rebecca Reeve

Rebecca.reeve@iqvia.com

Arm 003 Acalabrutinib - Paula Moreira

Paula.moreira@iqvia.com

Arm 004 MEDI3506 - Jennifer Allen

Jennifer.allan@iqvia.com

Arm 006 Zilucoplan – Katarzyna Wzietal

Katarzyna.wzietal@iqvia.com

A new master protocol and subsequent amendments to the arms should go live this week. The ethics committee/HRA have asked for a few corrections before issuing approval so IQVIA can offer formal training.

As you may already be aware key points of the amendment are to:

- Improve the consent process

- Increase recruitment eligibility

Items to note:

- **Tube labelling for central Labs** – Can sites ensure to label tubes clearly with the subject screening number from IWRS to facilitate prompt work from the labs.

- **Positive SARS COV test via a text message -** If the positive result is not available through the patient's GP notes, or directly from a lab result but a participant has received a text message confirming a positive result then the PI should review the text message and document in the patient source that they have verified a positive COV result via the text message received. Date and time of this review should be documented.